216394-07-9

Basic information

• Product Name: (1S,2S)-(+)-2-Benzyloxycyclohexylamine
• Synonyms: (1S-TRANS)-2-(PHENYLMETHOXY)CYCLOHEXANEAMINE;(1S,2S)-(+)-2-BENZYLOXYCYCLOHEXYLAMINE;(1S,2S)-(+)-1-Amino-2-benzyloxycyclohexane~(1S-trans)-(+)-2-(Phenylmethoxy)cyclohexanamine;(1S)-trans-(+)-2-(Phenylmethoxy)cyclohexanamine;(1S,2S)-(+)-1-Amino-2-benzyloxycyclohexane;(1S-trans)-2-(Phenylmethoxy) cyclohexaminetaneamine;(1S,2S)-(+)-2-BENZYLOXYCYCLOHEXYLAMINE: CHIPROS 99%;(1S,2S)-(+)-2-BENZYLOXYCYCLOHEXYLAMINE, CHIPROS 99+%, EE 99%
• CAS NO: 216394-07-9
• Molecular Formula: C13H19NO
• Molecular Weight: 205.3
• EINECS: -0
• Product Categories: CHIRAL CHEMICALS
• Mol File: 216394-07-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 79-80°C 0,08mm
• Flash Point: 79-80°C/0.08mm
• Appearance: /
• Density: 1.02
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.5275
• Storage Temp.: 2-8°C
• PKA: 9.80±0.70(Predicted)
• Sensitive: Air Sensitive
• BRN: 8981794
• CAS DataBase Reference: (1S,2S)-(+)-2-Benzyloxycyclohexylamine(CAS DataBase Reference)
• NIST Chemistry Reference: (1S,2S)-(+)-2-Benzyloxycyclohexylamine(216394-07-9)
• EPA Substance Registry System: (1S,2S)-(+)-2-Benzyloxycyclohexylamine(216394-07-9)

Safety Data

• Hazard Codes: Xn
• Statements: 34-36/37/38-22
• Safety Statements: 26-36/37/39-45
• RIDADR: 2735
• WGK Germany: 3
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 216394-07-9(Hazardous Substances Data)

Usage

General Description

(1S,2S)-(+)-2-Benzyloxycyclohexylamine is a chemical compound with the molecular formula C14H19NO. It is an enantiomer of (1R,2R)-(-)-2-Benzyloxycyclohexylamine, and it is commonly used in organic synthesis as a chiral auxiliary for enantioselective reactions. It is a white to off-white solid that is sparingly soluble in water but soluble in organic solvents. (1S,2S)-(+)-2-Benzyloxycyclohexylamine is also used as a building block in the synthesis of pharmaceuticals and agrochemicals, as well as in the production of chiral ligands for asymmetric catalysis. It is important to handle this compound with care, as it may cause irritation to the skin, eyes, and respiratory system.

InChI:InChI=1/C13H19NO/c14-12-8-4-5-9-13(12)15-10-11-6-2-1-3-7-11/h1-3,6-7,12-13H,4-5,8-10,14H2/t12-,13-/m0/s1

Upstream product

• 100-44-7 benzyl chloride 
• 85761-38-2 (+/-)-trans-2-benzyloxycyclohexan-1-ol 
• 18421-15-3 (±)-N-((1R,2R)-2-hydroxycyclohexyl)acetamide 
• 98454-36-5 N-((1R,2R)-2-Benzyloxy-cyclohexyl)-acetamide 
• 18421-15-3 (+/-)-N-(cis-2-hydroxy-cyclohexyl)-acetamide 
• 98454-36-5 N-((1R,2S)-2-Benzyloxy-cyclohexyl)-acetamide 

Downstream Products

• 745783-98-6 C₁₄H₁₇NOS 
• 40571-86-6 rac-(1R,2R)-2-(benzylamino)cyclohexanol 
• 141478-34-4 1-(N-benzylamino)-2-cyclohexanone 
• 121282-70-0 (+/-)-trans-1-hydroxy-2-tert-butoxycarbonylamino-cyclohexane 
• 1574347-88-8 N-[(1R,2R)-2-(benzyloxy)cyclohexyl]octadecane-1-sulphonamide 
• 1574347-89-9 N-[(1R,2R)-2-hydroxycyclohexyl]octadecane-1-sulphonamide 

Relevant articles and documents

Hybrid Organo- and Biocatalytic Process for the Asymmetric Transformation of Alcohols into Amines in Aqueous Medium

A hybrid organo- and biocatalytic system for the asymmetric conversion of racemic alcohols into amines was developed. Combining an organocatalyst, AZADO, an oxidant, NaOCl, and an enzyme, ω-transaminase, we implemented a one-pot oxidation-transamination sequential process in aqueous medium. The method showed broad substrate scope and was successfully applied to conventional secondary alcohols and sterically hindered β-substituted cycloalkanols, where a highly stereoselective dynamic asymmetric bioamination enabled us to set up both contiguous stereocenters with very high enantio- and diastereomeric ratio (>90% yield, >99% ee, and up to 49:1 dr).

Method for Producing O-Alkylated Aminoalcohols

A process for preparing O-alkylated amino alcohols by reacting N-unsubstituted or N-monosubstituted amino alkoxide salts with alkyl halides, the amino alkoxide salts being formed by means of alkali metal or alkaline earth metal hydroxides.

IL-8 RECEPTOR ANTAGONISTS

This invention relates to the use of phenyl ureas of formulas (I) and (II) in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8). The variables of (I) and (II) are defined herein. STR1